Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryota Hashimoto

Showing results (371-380 of 467) with videos related to

Pageof 47
Sort By:
Neuropsychopharmacology Reports|December 2, 2021
Association between the examination rate of treatment-resistant schizophrenia and the clozapine prescription rate in a nationwide dissemination and implementation studyNorio Yasui-Furukori, Hiroyuki Muraoka, Naomi Hasegawa, et al.
Schizophrenia Bulletin|June 20, 2020
Promoter Activity-Based Case-Control Association Study on SLC6A4 Highlighting Hypermethylation and Altered Amygdala Volume in Male Patients With SchizophreniaTempei Ikegame, Miki Bundo, Naohiro Okada, et al.
Asian Journal of Psychiatry|July 29, 2021
Characteristics of discharge prescriptions for patients with schizophrenia or major depressive disorder: Real-world evidence from the Effectiveness of Guidelines for Dissemination and Education (EGUIDE) psychiatric treatment projectNaoki Hashimoto, Norio Yasui-Furukori, Naomi Hasegawa, et al.
Cerebral Cortex (New York, N.Y. : 1991)|February 29, 2020
Polygenic Architecture of Human Neuroanatomical DiversityAnne Biton, Nicolas Traut, Jean-Baptiste Poline, et al.
Cerebral Cortex (New York, N.Y. : 1991)|April 7, 2020
Corrigendum: Polygenic Architecture of Human Neuroanatomical DiversityAnne Biton, Nicolas Traut, Jean-Baptiste Poline, et al.
Neuropsychopharmacology Reports|March 11, 2021
Improvements in the degree of understanding the treatment guidelines for schizophrenia and major depressive disorder in a nationwide dissemination and implementation studyShusuke Numata, Masahito Nakataki, Naomi Hasegawa, et al.
EMBO Molecular Medicine|January 6, 2010
The 28-amino acid form of an APLP1-derived Abeta-like peptide is a surrogate marker for Abeta42 production in the central nervous systemKanta Yanagida, Masayasu Okochi, Shinji Tagami, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 6, 2014
Transcriptome analysis of distinct mouse strains reveals kinesin light chain-1 splicing as an amyloid-β accumulation modifierTakashi Morihara, Noriyuki Hayashi, Mikiko Yokokoji, et al.
Schizophrenia Bulletin|April 15, 2020
Ethnicity-Dependent Effects of Schizophrenia Risk Variants of the OLIG2 Gene on OLIG2 Transcription and White Matter IntegrityHiroshi Komatsu, Hikaru Takeuchi, Yoshie Kikuchi, et al.
BMC Psychiatry|May 28, 2024
The effect of education regarding treatment guidelines for schizophrenia and major depressive disorders on psychiatrists' hypnotic medication prescribing behavior: a multicenter studyToshinori Nakamura, Ryuji Furihata, Naomi Hasegawa, et al.
Pageof 47

Showing results (371-380 of 467) with videos related to

Sort By:
Pageof 47
Neuropsychopharmacology Reports|December 2, 2021
Association between the examination rate of treatment-resistant schizophrenia and the clozapine prescription rate in a nationwide dissemination and implementation studyNorio Yasui-Furukori, Hiroyuki Muraoka, Naomi Hasegawa, et al.
Schizophrenia Bulletin|June 20, 2020
Promoter Activity-Based Case-Control Association Study on SLC6A4 Highlighting Hypermethylation and Altered Amygdala Volume in Male Patients With SchizophreniaTempei Ikegame, Miki Bundo, Naohiro Okada, et al.
Asian Journal of Psychiatry|July 29, 2021
Characteristics of discharge prescriptions for patients with schizophrenia or major depressive disorder: Real-world evidence from the Effectiveness of Guidelines for Dissemination and Education (EGUIDE) psychiatric treatment projectNaoki Hashimoto, Norio Yasui-Furukori, Naomi Hasegawa, et al.
Cerebral Cortex (New York, N.Y. : 1991)|February 29, 2020
Polygenic Architecture of Human Neuroanatomical DiversityAnne Biton, Nicolas Traut, Jean-Baptiste Poline, et al.
Cerebral Cortex (New York, N.Y. : 1991)|April 7, 2020
Corrigendum: Polygenic Architecture of Human Neuroanatomical DiversityAnne Biton, Nicolas Traut, Jean-Baptiste Poline, et al.
Neuropsychopharmacology Reports|March 11, 2021
Improvements in the degree of understanding the treatment guidelines for schizophrenia and major depressive disorder in a nationwide dissemination and implementation studyShusuke Numata, Masahito Nakataki, Naomi Hasegawa, et al.
EMBO Molecular Medicine|January 6, 2010
The 28-amino acid form of an APLP1-derived Abeta-like peptide is a surrogate marker for Abeta42 production in the central nervous systemKanta Yanagida, Masayasu Okochi, Shinji Tagami, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 6, 2014
Transcriptome analysis of distinct mouse strains reveals kinesin light chain-1 splicing as an amyloid-β accumulation modifierTakashi Morihara, Noriyuki Hayashi, Mikiko Yokokoji, et al.
Schizophrenia Bulletin|April 15, 2020
Ethnicity-Dependent Effects of Schizophrenia Risk Variants of the OLIG2 Gene on OLIG2 Transcription and White Matter IntegrityHiroshi Komatsu, Hikaru Takeuchi, Yoshie Kikuchi, et al.
BMC Psychiatry|May 28, 2024
The effect of education regarding treatment guidelines for schizophrenia and major depressive disorders on psychiatrists' hypnotic medication prescribing behavior: a multicenter studyToshinori Nakamura, Ryuji Furihata, Naomi Hasegawa, et al.
Pageof 47